About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Press Releases

2019 2018 2017
2016 2015 2014 2013 2012 2011
2010 2009 2008 2007 2006 2005

 
  November 2019
18 Nov Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research Download Pdf
12 Nov Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year Download Pdf
05 Nov Biocon's Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA Download Pdf
  October 2019
28 Oct Biocon Moves Up to Rank No. 6 on Science Careers' Top 20 Global Pharma & Biotech Employers List 2019 Download Pdf
23 Oct Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3% Download Pdf
10 Oct Biocon Biologics & Just - Evotec Biologics Sign Licensing Deal for a Biosimilar Asset Download Pdf
03 Oct Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia Download Pdf
  September 2019
26 Sep Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs Download Pdf
24 Sep Biocon Biologics Expands its R&D Footprint Through Acquisition Download Pdf
20 Sep Company Statement: U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru Download Pdf
12 Sep Biocon Licenses Three Generic Formulation Products to China Medical System Holdings Download Pdf
  August 2019
31 Aug Company Statement: U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged Download Pdf
31 Aug Company Statement: U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru Download Pdf
22 Aug Biocon's Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity Download Pdf
01 Aug Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri, in Australia Download Pdf
  July 2019
25 Jul Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr; Small Molecules up 20% at Rs 480 Cr, Biologics Up 96% at Rs 490 Cr Download Pdf
08 Jul Company Statement: Pre -Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia Download Pdf
  June 2019
14 Jun Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification Download Pdf
  May 2019
22 May Health Canada Approves Biocon and Mylan's Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers Download Pdf
16 May Biocon and Mylan to Present Final Overall Survival Data for Ogivri ™(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting Download Pdf
07 May Company Statement: Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan Download Pdf
  April 2019
25 Apr Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%;EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr Board Recommends 1: 1 Bonus Shares Download Pdf
  March 2019
13 Mar Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia Download Pdf
06 Mar Company Statement : Biocon Facility Completes Pre Approval U.S. FDA Inspection Download Pdf
01 Mar Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited Download Pdf
  February 2019
18 Feb Company Statement : Biocon Facilities complete Pre Approval U.S.FDA lnspection Download Pdf
08 Feb Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S. Download Pdf
  January 2019
24 Jan Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59% Download Pdf
   
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved